Insmed (INSM) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseZacks Investment Research · 3 days ago
Insmed Appoints Two New Directors to Its BoardPRNewsWire · 6 days ago
Insmed Launches BRINSUPRI® Tablets 25 mg (brensocatib hydrate) for the Treatment of Non-Cystic Fibrosis Bronchiectasis in JapanPRNewsWire · Oct 19, 2026
Insmed Features the Global Phase 3 PALM Clinical Development Program Evaluating Treprostinil Palmitil Inhalation Powder (TPIP) at CHEST 2026PRNewsWire · Oct 15, 2026
Insmed to Present New Data Across Its Respiratory Portfolio at CHEST 2026 and IDWeek 2026PRNewsWire · Oct 14, 2026
Perpetual Ltd Acquires 5,760 Shares of Insmed, Inc. $INSMDefense World · Oct 14, 2026Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 6, 2026 | -$0.67 | -$0.06 | Beat |
| May 7, 2026 | -$0.96 | -$0.76 | Beat |
| Feb 19, 2026 | -$1.07 | -$1.54 | Miss |
| Oct 30, 2025 | -$1.33 | -$1.75 | Miss |
| Aug 7, 2025 | -$1.30 | -$1.70 | Miss |
| May 8, 2025 | -$1.34 | -$1.42 | Miss |